- Home
- GORV vs NRSN Comparison
GORV vs NRSN Comparison
Compare GORV & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GORV
- NRSN
- Stock Information
- Founded
- GORV 1976
- NRSN 2017
- Country
- GORV United States
- NRSN Israel
- Employees
- GORV N/A
- NRSN N/A
- Industry
- GORV Retail-Auto Dealers and Gas Stations
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- GORV Consumer Discretionary
- NRSN Health Care
- Exchange
- GORV Nasdaq
- NRSN Nasdaq
- Market Cap
- GORV 26.5M
- NRSN 26.0M
- IPO Year
- GORV 2015
- NRSN 2021
- Fundamental
- Price
- GORV $0.22
- NRSN $0.99
- Analyst Decision
- GORV Hold
- NRSN Hold
- Analyst Count
- GORV 2
- NRSN 1
- Target Price
- GORV $2.00
- NRSN N/A
- AVG Volume (30 Days)
- GORV 156.5K
- NRSN 130.1K
- Earning Date
- GORV 05-14-2025
- NRSN 04-07-2025
- Dividend Yield
- GORV N/A
- NRSN N/A
- EPS Growth
- GORV N/A
- NRSN N/A
- EPS
- GORV N/A
- NRSN N/A
- Revenue
- GORV $871,562,000.00
- NRSN N/A
- Revenue This Year
- GORV $15.65
- NRSN N/A
- Revenue Next Year
- GORV $20.54
- NRSN N/A
- P/E Ratio
- GORV N/A
- NRSN N/A
- Revenue Growth
- GORV N/A
- NRSN N/A
- 52 Week Low
- GORV $0.20
- NRSN $0.51
- 52 Week High
- GORV $4.00
- NRSN $1.50
- Technical
- Relative Strength Index (RSI)
- GORV 32.94
- NRSN 44.13
- Support Level
- GORV $0.23
- NRSN $0.97
- Resistance Level
- GORV $0.27
- NRSN $1.04
- Average True Range (ATR)
- GORV 0.04
- NRSN 0.09
- MACD
- GORV 0.01
- NRSN 0.00
- Stochastic Oscillator
- GORV 22.16
- NRSN 57.04
About GORV Lazydays Holdings Inc.
Lazydays Holdings Inc operates recreational vehicle dealerships. It provides products and services for RV owners and outdoor enthusiasts. The company generates revenue by providing a full spectrum of RV products: New and pre-owned RV sales, RV parts and services, financing and insurance products, third-party protection plans, after-market parts and accessories, and RV camping facilities.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.